Simplex Trading’s CytomX Therapeutics CTMX Stock Holding History

Simplex Trading’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.47M	Buy	311,900 +310,700	+25,892%	+$1.58M	﹤0.01%	2106
2025 Q4	$5.11K	Sell	1,200 -11,000	-90%	-$41.8K	﹤0.01%	7419
2025 Q3	$38K	Sell	12,200 -16,600	-58%	-$37.4K	﹤0.01%	6717
2025 Q2	$65K	Buy	+28,800	New	+$46.4K	﹤0.01%	5656
2023 Q2	–	Sell	-1,800	Closed	-$2K	–	9115
2023 Q1	$2K	Buy	+1,800	New	+$4.07K	﹤0.01%	8431
2022 Q2	–	Sell	-1,200	Closed	-$3K	–	10112
2022 Q1	$3K	Sell	1,200 -500	-29%	-$1.92K	﹤0.01%	9675
2021 Q4	$7K	Buy	1,700 +300	+21%	+$1.76K	﹤0.01%	9283
2021 Q3	$9K	Hold	1,400	–	–	﹤0.01%	8984
2021 Q2	$8K	Buy	1,400 +1,390	+13,900%	+$10.8K	﹤0.01%	9203
2021 Q1	$7K	Buy	+10	New	+$79	﹤0.01%	8062
2017 Q4	–	Sell	-3	Closed	-$1K	–	6080
2017 Q3	$1K	Buy	+3	New	+$47	﹤0.01%	5383

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Simplex Trading's CTMX Position: Q1 2026 in Review

Simplex Trading increased its CytomX Therapeutics (CTMX) stake by 933% in Q1 2026, buying an estimated $1.14M and bringing the position to 248,438 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2330.

Simplex Trading first reported a position in CTMX in Q3 2017 and has held it in 17 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

Simplex Trading held 248,438 shares of CytomX Therapeutics worth $1.17M as of Q1 2026.
Simplex Trading bought 224,387 CytomX Therapeutics shares in Q1 2026, an estimated $1.14M.
CytomX Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #2330 holding.
Simplex Trading first reported a position in CytomX Therapeutics in Q3 2017 and has held it in 17 quarters since.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.